Who are P2Y12 inhibitor de-escalation's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Group P+T, Acetylsalicylic Acid + clopidogrel, Group P+P, heparin + clopidogrel + aspirin, prasugrel / clopidogrel, ticagrelor + ASA.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/p2y12-inhibitor-de-escalation.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

P2Y12 inhibitor de-escalation — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

P2Y12 inhibitor de-escalation (P2Y12 inhibitor de-escalation) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: P2Y12 inhibitor. Area: Cardiovascular.

phase 3 P2Y12 inhibitor P2Y12 receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

P2Y12 inhibitor de-escalation (P2Y12 inhibitor de-escalation) — Azienda Ospedaliera Universitaria Policlinico "G. Martino". P2Y12 inhibitors block the action of ADP on the P2Y12 receptor, preventing platelet activation and aggregation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
P2Y12 inhibitor de-escalation TARGET	P2Y12 inhibitor de-escalation	Azienda Ospedaliera Universitaria Policlinico "G. Martino"	phase 3	P2Y12 inhibitor	P2Y12 receptor
Group P+T	Group P+T	Huazhong University of Science and Technology	marketed	P2Y12 inhibitor	P2Y12 receptor
Acetylsalicylic Acid + clopidogrel	Acetylsalicylic Acid + clopidogrel	Hospital Universitari Vall d'Hebron Research Institute	marketed	Dual antiplatelet agent	Cyclooxygenase-1 (COX-1) and P2Y12 receptor
Group P+P	Group P+P	Huazhong University of Science and Technology	marketed	P2Y12 inhibitor	P2Y12 receptor
heparin + clopidogrel + aspirin	heparin + clopidogrel + aspirin	Centre Hospitalier de PAU	marketed	Antiplatelet and anticoagulant combination	Thrombin, Factor Xa, Cyclooxygenase, P2Y12 receptor
prasugrel / clopidogrel	prasugrel / clopidogrel	Assistance Publique - Hôpitaux de Paris	marketed	P2Y12 receptor antagonist (thienopyridine)	P2Y12 receptor
ticagrelor + ASA	ticagrelor + ASA	Peking University Third Hospital	marketed	Dual antiplatelet agent	P2Y12 receptor (ticagrelor); cyclooxygenase (aspirin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (P2Y12 inhibitor class)

Huazhong University of Science and Technology · 2 drugs in this class
Azienda Ospedaliera Universitaria Policlinico "G. Martino" · 1 drug in this class
Shanghai Jiao Tong University School of Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). P2Y12 inhibitor de-escalation — Competitive Intelligence Brief. https://druglandscape.com/ci/p2y12-inhibitor-de-escalation. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab